Department of Upper Gastrointestinal and Bariatric Surgery, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore.
Obes Surg. 2021 Mar;31(3):949-964. doi: 10.1007/s11695-020-05094-y. Epub 2020 Nov 6.
One-anastomosis gastric bypass (OAGB) was established as a recognized bariatric procedure in the 2018 International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) position statement. This study evaluates the outcomes of revisional OAGB (rOAGB) after a restrictive index procedure, and to compare it to revisional RYGB (rRYGB).
A literature search was performed according to the PRISMA guidelines on papers published from inception till February 2020. Original studies involving patients who underwent rOAGB after a primary failed restrictive procedure were included. The primary outcome measured was postrOAGB weight loss. Secondary outcome measures include comorbidity resolution, operative duration, length of stay, morbidity, and mortality.
A total of 21 studies with 1377 patients were included. Five studies compared rOAGB versus rRYGB. Majority of the patients (76%) were female, with mean age of 43.5 years old. Mean body mass index (BMI) before revisional surgery was 41.6 kg/m. The most common biliopancreatic limb length was 200 cm. Percentage of excess weight loss after rOAGB increases to a maximum of 76.0% at 48 months postsurgery. rOAGB resulted in a pooled prevalence of diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea resolution of 74.9%, 48.4%, 63.2%, and 75.7% respectively. When compared to rRYGB, rOAGB demonstrated greater weight loss, comparable metabolic syndrome resolution, but with a shorter operating time. Morbidity and mortality rates were low across all studies.
rOAGB has potential as an alternative revisional surgery, with weight loss profiles and rates of metabolic syndrome resolution that are comparable to rRYGB.
单吻合胃旁路术(OAGB)在 2018 年国际肥胖与代谢紊乱外科学联合会(IFSO)立场声明中被确立为一种公认的减重手术。本研究评估了初次限制性手术后再次 OAGB(rOAGB)的结果,并将其与再次 RYGB(rRYGB)进行比较。
根据 PRISMA 指南,对从成立到 2020 年 2 月发表的论文进行了文献检索。纳入了初次失败的限制性手术后行 rOAGB 的患者的原始研究。主要测量的结果是 rOAGB 术后的体重减轻。次要结果测量包括合并症的解决、手术时间、住院时间、发病率和死亡率。
共纳入 21 项研究,涉及 1377 例患者。有 5 项研究比较了 rOAGB 与 rRYGB。大多数患者(76%)为女性,平均年龄为 43.5 岁。再次手术前的平均体重指数(BMI)为 41.6kg/m。最常见的胆胰支长度为 200cm。rOAGB 术后最大的多余体重减轻百分比增加到 76.0%,术后 48 个月。rOAGB 导致糖尿病、高血压、高脂血症和阻塞性睡眠呼吸暂停的缓解率分别为 74.9%、48.4%、63.2%和 75.7%。与 rRYGB 相比,rOAGB 显示出更大的体重减轻,相似的代谢综合征缓解率,但手术时间更短。所有研究的发病率和死亡率都很低。
rOAGB 作为一种替代的再次手术具有潜力,其体重减轻情况和代谢综合征缓解率与 rRYGB 相当。